Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/14/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
89.66(c) 88.88(c) 89.36(c) 88.46(c) 87.45(c) Last
3 919 818 4 492 281 3 464 882 3 657 505 5 427 633 Volume
+1.11% -0.87% +0.54% -1.01% -1.14% Change
More quotes
Financials (USD)
Sales 2020 34 120 M
EBIT 2020 7 754 M
Net income 2020 4 460 M
Debt 2020 10 170 M
Yield 2020 1,60%
Sales 2021 36 551 M
EBIT 2021 8 553 M
Net income 2021 5 538 M
Debt 2021 5 535 M
Yield 2021 1,76%
P/E ratio 2020 34,6x
P/E ratio 2021 28,2x
EV / Sales2020 4,83x
EV / Sales2021 4,38x
Capitalization 155 B
More Financials
Company
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - vascular devices (30.9%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - diagnostic... 
More about the company
Surperformance© ratings of Abbott Laboratories
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBOTT LABORATORIES
04:32pABBOTT LABORATORIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
10:58aABBOTT : Declares 385th Consecutive Quarterly Dividend
PR
02/18ABBOTT : Introduces Next-Generation Heart Rhythm Management Devices in Europe, F..
PR
02/11ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)
AQ
02/05WALL STREET STOCK EXCHANGE : Tiffany is part of LVMH, Tesla gives some bad news,..
02/04ABBOTT LABORATORIES : Gets FDA Breakthrough Designation for Fully Implantable He..
DJ
02/04ABBOTT : 's In-Development Fully Implantable Heart Pump System Earns FDA's Break..
PR
02/03ABBOTT : Announces First-of-Its-Kind Trial to Assess New Therapy Option for Peop..
PR
01/31ABBOTT LABORATORIES : Tendyne device receives world's first ce mark for transcat..
AQ
01/30ABBOTT : 's Tendyne™ Device Receives World's First CE Mark for Transcathet..
PR
01/27ABBOTT LABORATORIES : Receives expanded indication from the u.s. fda for directi..
AQ
01/24Abbott Laboratories Gets Expanded Indication for Infinity Deep Brain Stimulat..
DJ
01/24ABBOTT : Receives Expanded Indication From the U.S. FDA for Directional Deep Bra..
PR
01/24ABBOTT LABORATORIES : New quality of life and functional improvement data from a..
AQ
01/22Incoming Abbott CEO says not looking to do any deals
RE
More news
News in other languages on ABBOTT LABORATORIES
02/12STOCK MARKET PARIS : Im-per-tur-ba-bles !
02/06AVIS D'ANALYSTES DU JOUR : BNP Paribas, Renault, Ingenico, Melexis, Mithra, Infi..
02/06STOCK MARKET PARIS : Une épidémie, quelle épidémie ?
02/05EN DIRECT DES MARCHES : BNP Paribas, LVMH, Vinci, Aperam, DBV Technologies, e..
02/05STOCK MARKET PARIS : Un moral à toute épreuve
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Sector news : Medical Equipment
11:41aPharmaceutical companies develop system to better track counterfeit drugs
RE
02/20FISHER & PAYKEL HEALTHCARE : F&P Healthcare Raises Fiscal Year Earnings, Revenue..
DJ
02/20SMITH & NEPHEW : +Nephew forecasts sales growth after best year since 2010
RE
02/18MEDTRONIC : Raises 2020 Guidance, Sets 4Q Outlook
DJ
02/18MEDTRONIC : 3Q Profit, Sales Rise
DJ
More sector news : Medical Equipment
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 99,28  $
Last Close Price 87,45  $
Spread / Highest target 25,8%
Spread / Average Target 13,5%
Spread / Lowest Target -10,8%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Robert B. Ford President & Chief Operating Officer
Brian Bernard Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES1.84%156 438
MASIMO CORPORATION15.29%9 780
NOVOCURE LIMITED10.29%9 198
PENUMBRA, INC.16.36%6 674
ASAHI INTECC CO., LTD.0.33%6 583
GETINGE0.66%4 853